eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
5/2016
vol. 20
 
Share:
Share:
abstract:
Case report

Axitinib in sequential therapy in metastatic renal cell carcinoma

Agata Kuchar
,
Beata Hryciuk
,
Rafał Stec
,
Michał Mączewski
,
Cezary Szczylik

Contemp Oncol (Pozn) 2016; 20 (5): 418-420
Online publish date: 2015/05/28
View full text Get citation
 
PlumX metrics:
Efficacy of new molecularly targeted drugs in the treatment of renal cell carcinoma (RCC), confirmed in clinical studies in relation to survival and prolongation of time to progression, has became a big chance for patients with metastatic renal cell cancer. Axitinib is a potent and selective receptor tyrosine kinase for vascular endothelial growth factor (VEGFR-1, -2, -3), platelet-derived growth factor  (PDGRF-) and c-KIT.

This is a case report of a 57-year old female patient with a history of left nephrectomy due to clear cell renal cell carcinoma. The patient had received three prior systemic treatments (interferon – sorafenib – everolimus). After consecutive progression the patient was qualified to 4th line therapy – axitinib at a dose of 5 mg twice daily. Partial response to treatment was achieved. After 6 months therapy was stopped due to the disease progression. The total time to progression was 37.5 months. The total survival time from the disease diagnosis was 45 months.

Based on literature date and own experience we showed that sequential treatment RCC is associated with improved survival. In summary, axitinib may be an effective drug after failure of tyrosine-kinase inhibitor (TKI) therapy in previous lines of therapy.
keywords:

renal cell carcinoma, sequential therapy, axitinib, targeted therapies

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.